[ad_1]
With robust three-month efficiency and vital upside potential, Shattuck Labs, Inc. (NASDAQ:STTK) secures a spot on our record of the 12 sizzling penny shares to put money into proper now.
Pixabay/Public Area
Highlighting the SL-325’s Part 1 readout, anticipated in Q2 2026, H.C. Wainwright’s Joseph Pantginis reiterated a “Maintain” ranking on Shattuck Labs, Inc. (NASDAQ:STTK) on November 7, 2025. The analyst believes the drug holds vital scientific potential, boosting the analyst’s confidence. The drug stays a key development catalyst, with DR3-based bispecific antibodies anticipated to offer longer-term upside. Pantginis additionally cited the corporate’s strong monetary place as seen via its money and investments stability of $86.10 million. Thus, the analyst sees a balanced danger profile for the corporate, with SL-325 remaining central to the funding case.
In the meantime, Shattuck Labs, Inc. (NASDAQ:STTK) introduced its third-quarter 2025 outcomes on November 6, 2025. The corporate, nonetheless in its improvement stage, famous R&D declining to $7.60 million, whereas G&A bills totaled $4.10 million. Reflecting disciplined execution, Shattuck Labs reaffirmed development of the Part 1 SL-325 trial. It additionally reported continued progress towards deciding on a bispecific candidate in 2026. With a wholesome money stability, the corporate appears to be like well-positioned to advance the drug into Part 2 trials. Web loss for the quarter was $10.1 million, or $0.14 per primary and diluted share.
Shattuck Labs, Inc. (NASDAQ:STTK) focuses on creating novel therapies for autoimmune and inflammatory ailments. Its SL-325 drug goals for a whole blockade of the validated DR3/TL1A pathway.s
Whereas we acknowledge the potential of STTK as an funding, we imagine sure AI shares provide higher upside potential and carry much less draw back danger. When you’re on the lookout for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 10 Greatest Small-Cap Biotech Shares to Purchase In line with Analysts and 11 Missed Tech Shares to Make investments In.
Disclosure: None.
[ad_2]
